Unlike other approaches, Allurion’s balloon does not require surgery, endoscopy, or anaesthesia. After around four months, the balloon releases the liquid on its own and it passes out of the ...

Studies have previously demonstrated successful use of the Allurion Balloon in combination with short-term use of GLP-1 agonists. In a randomized, double-blind study, published in Obesity Surgery ...

Allurion Technologies Inc. is cleared by regulators in France to resume sales of its swallowable gastric balloon to treat obesity, in the country. Last summer, the company withdrew the Allurion ...

today announced that it is relaunching the Allurion Balloon in France after ANSM, the French regulatory authority, cleared Allurion to resume sales. “We are thrilled the Allurion Balloon will ...

These patents, both of which are scheduled to issue on March 11, 2025, provide additional claims for an enhanced, next-generation version of Allurion’s proprietary Balloon technology for the ...

The Allurion Balloon, a non-surgical gastric balloon for weight loss, has previously shown promise when used in tandem with GLP-1 agonists. A study published in Obesity Surgery revealed that patients ...

The Allurion Program is a weight loss platform that combines the Allurion Gastric Balloon, a swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite including ...

Studies have previously demonstrated successful use of the Allurion Balloon in combination with short-term use of GLP-1 agonists. In a randomized, double-blind study, published in Obesity Surgery ...